Skip to main content
BTC / USDTCRYPTO107,400+2.19%ETH / USDTCRYPTO3,840+2.13%SOL / USDTCRYPTO182.40−1.99%BNB / USDTCRYPTO652.30+0.66%XRP / USDTCRYPTO2.2150+1.61%DOGE / USDTCRYPTO0.3850−1.79%TON / USDTCRYPTO5.240+2.34%AVAX / USDTCRYPTO42.60−2.07%LINK / USDTCRYPTO22.40+2.28%ADA / USDTCRYPTO1.0520−1.68%TRX / USDTCRYPTO0.3300+0.92%DOT / USDTCRYPTO8.420+2.93%BTC / USDTCRYPTO107,400+2.19%ETH / USDTCRYPTO3,840+2.13%SOL / USDTCRYPTO182.40−1.99%BNB / USDTCRYPTO652.30+0.66%XRP / USDTCRYPTO2.2150+1.61%DOGE / USDTCRYPTO0.3850−1.79%TON / USDTCRYPTO5.240+2.34%AVAX / USDTCRYPTO42.60−2.07%LINK / USDTCRYPTO22.40+2.28%ADA / USDTCRYPTO1.0520−1.68%TRX / USDTCRYPTO0.3300+0.92%DOT / USDTCRYPTO8.420+2.93%
PreciosAutoresArchivo de ediciones
/
Precios
Comenzar→
macroJun 25, 2026, 10:47 AM

Eli Lilly Announces Medicare GLP-1 Bridge Program for Obesity Meds

Eli Lilly will offer its obesity drugs Zepbound and Mounjaro to eligible Medicare Part D patients starting July 1, 2026, at $50/month. An estimated 20 million beneficiaries may qualify for coverage through the end of 2027.

LLY

Eli Lilly (LLY) has introduced a Medicare GLP-1 Bridge Program that will allow eligible Medicare Part D patients to access the company's obesity medicines from July 1, 2026 through December 31, 2027. The program is expected to make Zepbound or Mounjaro available at $50 per month.

According to Eli Lilly, approximately 20 million Medicare patients may qualify for obesity medicine coverage under this initiative. This represents a significant expansion of access to GLP-1 therapies for the Medicare population.

Source: First Squawk